Search for: "SANDOZ, INC."
Results 301 - 320
of 679
Sort by Relevance
|
Sort by Date
9 Dec 2014, 9:43 pm
By Andrew Williams -- Last year, Sandoz filed a declaratory judgment action against Amgen and Roche related to its etanercept biosimilar drug product, which it developed to compete with Amgen's Enbrel® TNF inhibitor. [read post]
8 Dec 2014, 10:00 pm
In Sandoz Inc. v. [read post]
8 Dec 2014, 12:42 pm
” MedImmune, Inc. [read post]
2 Dec 2014, 12:27 pm
Sandoz Inc., 13-854. [read post]
10 Nov 2014, 2:18 pm
USA, Inc. v. [read post]
7 Nov 2014, 9:17 am
Sandoz, wherein there was no stipulation for the purposes of seeking an appeal. [read post]
20 Oct 2014, 12:09 pm
Sandoz, Inc. [read post]
17 Oct 2014, 5:09 pm
Sandoz, Inc. [read post]
17 Oct 2014, 7:23 am
Sandoz, Inc., emphasizing that “[l]ast year’s patent decisions revealed a strong preference by the Supreme Court to tell the Federal Circuit that it should stop thinking of itself as Lord of the Patents, and that ‘supreme’ means just what it sounds like. [read post]
16 Oct 2014, 7:10 am
Sandoz, Inc. [read post]
16 Oct 2014, 3:12 am
Sandoz, Inc. [read post]
15 Oct 2014, 11:52 am
Sandoz, Inc., No. 13-854. [read post]
15 Oct 2014, 10:30 am
Sandoz, Inc., over the differing — and maybe competing — roles of trial judges and a specialized federal appeals court that has a major role in shaping the law of inventions. [read post]
14 Oct 2014, 9:59 pm
Sandoz Inc. -- The End of Cybor Corp.? [read post]
13 Oct 2014, 9:01 am
Sandoz. [read post]
9 Oct 2014, 9:59 pm
Sandoz Inc. case to determine whether appellate courts should afford any deference to a trial court's claim construction determination. [read post]
6 Oct 2014, 5:36 am
Two different articles look ahead at next month’s oral argument in the securities case Omnicare, Inc. v. [read post]
29 Sep 2014, 9:42 pm
Sandoz Inc. will address whether appellate courts should afford any deference to a trial court's claim construction determination. [read post]
25 Aug 2014, 9:35 am
Sandoz Pharm. [read post]
29 Jul 2014, 12:08 pm
The reference product, Neupogen®, which brought maker Amgen Inc. $1.4 billion in sales in 2013, is a biologic used […] [read post]
